TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT03623763

Intervention type: DIAGNOSTIC_TEST
Intervention: Serologic tests of blood samples
Description: Five milliliters of peripheral venous blood will be (after 8-12 hours of fasting) from each participant and will be collected into Human Tube Serum Gel - C/A for ELISA. All blood samples will be collected in August and January. Serum levels of 25(OH) VD and TNF-α, IFN-γ, IL-4 and IL-6 will be detected by ELISA technique

Intervention type: DIAGNOSTIC_TEST
Intervention: Serologic tests of blood samples
Description: Five milliliters of peripheral venous blood will be (after 8-12 hours of fasting) from each participant and will be collected into Human Tube Serum Gel - C/A for ELISA. All blood samples will be collected in August and January. Serum levels of 25(OH) VD and TNF-α, IFN-γ, IL-4 and IL-6 will be detected by ELISA technique

Intervention type: DIAGNOSTIC_TEST
Intervention: Serologic tests of blood samples
Description: Five milliliters of peripheral venous blood will be (after 8-12 hours of fasting) from each participant and will be collected into Human Tube Serum Gel - C/A for ELISA. All blood samples will be collected in August and January. Serum levels of 25(OH) VD and TNF-α, IFN-γ, IL-4 and IL-6 will be detected by ELISA technique
Study: NCT00909506

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Control: Receive placebo pill once every evening on 1\~2 weeks.~Receive placebo pill in every morning and evening on 3\~24 weeks (twice a day).

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Metformin
Description: Metformin 500 mg/d: Receive oral metformin 500 mg dose once daily on 1\~2 weeks.~Receive placebo pill in every morning and oral metformin 500 mg in every evening on 3\~24 weeks.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Metformin
Description: Metformin 1000 mg/d : Receive oral metformin 500 mg dose once daily on 1\~2 weeks. (Dose-escalate)~Receive oral metformin 500 mg in every morning and evening on 3\~24 weeks (metformin 500 mg \* twice a day = 1000 mg per day).
Study: NCT03647826

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mind Power Intervention
Description: The intervention has a total sample of 110 schoool classes, which are devided in two arms: Mind Power Intervention Group 1 or Mind Power Intervention Group 2

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mind Power Intervention
Description: The intervention has a total sample of 110 schoool classes, which are devided in two arms: Mind Power Intervention Group 1 or Mind Power Intervention Group 2
Study: NCT02637765

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Increased Physical Activity
Description: Patients will receive a program of increased physical activity starting from 5000 steps/day up to 12000 steps/day after 8 weeks and an 8-week recreational program of brisk walking/running (3 times a week).
Study: NCT00479336

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: OPC-41061 7.5mg
Description: 7.5mg, 1 tablet a day

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: OPC-41061 placebo
Description: placebo, 1 tablet a day

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: OPC-41061 15mg
Description: 15mg, 1 tablet a day

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: OPC-41601 30mg
Description: 30mg, 1 tablet a day
Study: NCT00108862

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Strategy: Immediate ART
Description: The intervention is the strategy of initiating antiretroviral therapy (ART) after approximately 2 weeks of rifampin (RIF)- or other rifamycin-based TB treatment according to in-country national TB treatment guidelines. The study-provided ART is efavirenz (EFV) 600 mg (1 tablet orally), emtricitabine (FTC) 200 mg (1 capsule orally), and tenofovir disoproxil fumarate (TDF) 300 mg (1 tablet orally) daily. Substitutions with other locally available U.S. Food and Drug Administration (FDA)-approved or tentatively approved antiretrovirals that are compatible with TB treatment may be used at the discretion of the site investigator. The TB treatment will be supplied and monitored by the host country TB control program.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Strategy: Deferred ART
Description: The intervention is the strategy of initiating ART either after 8-12 weeks of RIF- or other rifamycin-based TB treatment according to in-country national TB treatment guidelines. The study-provided ART is EFV 600 mg (1 tablet orally), FTC 200 mg (1 capsule orally), and TDF 300 mg (1 tablet orally) daily. Initiation outside of these windows, on a case by case basis, is permitted at the discretion of the site investigator. Substitutions with other locally available U.S. FDA-approved or tentatively approved antiretrovirals that are compatible with TB treatment may be used at the discretion of the site investigator. The TB treatment will be supplied and monitored by the host country TB control program.
Study: NCT01426958

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: afatinib
Description: standard therapeutic dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ritonavir + afatinib
Description: simultaneous intake of ritonavir and afatinib on second treatment day

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ritonavir + afatinib
Description: on the second treatment day the first ritonavir tablet will be taken 6 hours after the afatinib tablet
Study: NCT04609631

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Tai Chi
Description: 24-form Tai Chi will be performed for 12 weeks. Each session contains a warm-up period (10 minutes), a Tai Chi period (40 minutes) and a cool-down period (10 minutes).

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Tai Chi
Description: 24-form Tai Chi will be performed for 12 weeks. Each session contains a warm-up period (10 minutes), a Tai Chi period (40 minutes) and a cool-down period (10 minutes).

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Tai Chi
Description: 24-form Tai Chi will be performed for 12 weeks. Each session contains a warm-up period (10 minutes), a Tai Chi period (40 minutes) and a cool-down period (10 minutes).

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: CBT
Description: CBT will be performed once a week for 12 weeks. Each session lasts for 1 hour.
Study: NCT05992792

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Internet
Description: Internet connection in their mobile phone and WI-Fi. Participants push message cancer prevention from the recomendations ECAC. Second randomization for received 2 notifications (push) per week or frequency of 7 SMS notifications per week.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Whithout internet
Description: Second randomization for received 2 notifications (push) per week or frequency of 7 SMS notifications per week.
Study: NCT04002414

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Sufficient physical activity
Description: Physical activity at the recommended levels by the US Health and Human Services Department: 75 minutes a week of vigorous activity or 150 minutes a week of moderate activity.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Sufficient physical activity
Description: Physical activity at the recommended levels by the US Health and Human Services Department: 75 minutes a week of vigorous activity or 150 minutes a week of moderate activity.
Study: NCT04590404

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Metabolism Informed Smoking Treatment (Nicotine metabolite ratio (NMR)-based selection of pharmacotherapy)
Description: Nicotine metabolite ratio (NMR)-based selection of pharmacotherapy. NMR is a blood test to measure how fast the body breaks down nicotine.
Study: NCT04002414

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Insufficient physical activity
Description: Physical activity less than the recommended levels by the US Health and Human Services Department: 75 minutes a week of vigorous activity or 150 minutes a week of moderate activity.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Insufficient physical activity
Description: Physical activity less than the recommended levels by the US Health and Human Services Department: 75 minutes a week of vigorous activity or 150 minutes a week of moderate activity.
Study: NCT01734551

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Morphine
Description: Start at 0.4mg/kg/day (divided every 3-4 hours, given with feeds. Dose may be increased 25% of initial dose until symptoms are stable, up to 1 mg/kg/day.~Once stable for 72 hrs, weaning may begin (decrease 10% of max dose, every other day). When total dose is \<0.1mg/kg/day, may discontinue.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Clonidine
Description: Initial dose is 5 mcg/kg/day (divided every 3-4 hrs, given with feeds). Will increase 25% of initial dose every 12-24 hrs until stable, up to 12 mcg/kg/day. Dose is unchanged for 72 hours once stable, then may decrease by 10% every other day. If re-escalation is required, the previous dose may be used with 72 hours for stabilizing.
Study: NCT01358227

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PR104
Description: Dose escalation of PR104 to determine maximum tolerated dose for weekly administration
Study: NCT00662974

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: perineal massage with almond oil during the second stage of labor
Description: 30 ml of oil applied during labor
Study: NCT02144740

Intervention type: DIETARY_SUPPLEMENT
Group type: OTHER
Intervention: NWT-03, an egg-white protein hydrolysate
Description: For placebo comparator, a combination of sweetener + aroma, which was equal to the combination used in the intervention period, was given

Intervention type: DIETARY_SUPPLEMENT
Group type: OTHER
Intervention: NWT-03, an egg-white protein hydrolysate
Description: For placebo comparator, a combination of sweetener + aroma, which was equal to the combination used in the intervention period, was given

Intervention type: DIETARY_SUPPLEMENT
Group type: OTHER
Intervention: Placebo
Description: A combination of sweetener + aroma , which was equal to the combination used in the intervention period, was given.

Intervention type: DIETARY_SUPPLEMENT
Group type: OTHER
Intervention: Placebo
Description: A combination of sweetener + aroma , which was equal to the combination used in the intervention period, was given.
Study: NCT00980551

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: subtenon Carboplatin
Description: Available in 50mg, 150mg, 450 mg, 600mg vials. It is provided as a premixed aqueous solution or lyophilized powder for injection given on day 1/week 10 (cycles 1-3).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Topotecan Hydrochloride
Description: Each vial contains topotecan hydrochloride equivalent to 4 mg of topotecan as free base. Given intravenously on days 1-5 of each week (cycles 1-6).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vincristine
Description: Each vial contains vincristine sulfate, 1 mg; mannitol, 100 mg; sterile water for injection; Acetic acid and sodium acetate are added for pH control. Given intravenously on day 1/week 1 (cycles 1-6).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Filgrastim
Description: Supplied as a clear solution in 300 mcg/ml 1 ml or 1.6 ml vials and prefilled syringes containing 300mcg/0.5mL or 480mcg/0.8mL. Given intravenously on day 6 of each week (cycles 1-6).
Study: NCT04277091

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: High-intensity interval training
Description: Arm-cranking exercise

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Moderate-intensity continuos training
Description: Arm-cranking exercise
Study: NCT03007394

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lorcaserin
Description: Lorcaserin Capsule

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Oral Capsule
Description: sugar pill to mimic lorcaserin 10mg capsule
Study: NCT02552316

Intervention type: DEVICE
Group type: OTHER
Intervention: NB-UVB Phototherapy
Study: NCT03132051

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: steroid injection
Description: ultrasound-guided steroid injection using 1ml of 10 mg (10mg/ml) triamcinolone acetonide
Study: NCT03577665

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: curative proton therapy
Description: Patients who meet the selection criteria are selected, signed for consent, and treated with proton therapy alone at 7200 cGy / 15 fractions, 5 times a week for 3 weeks
Study: NCT00151775

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: olmesartan medoxomil
Description: Cohorts A and B: 2.5mg to 40mg olmesartan, as a suspension (depending on weight), once daily. Tablets were used to prepare a suspension.~Cohort C: 0.3mg/kg olmesartan ,as a suspension, once daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: olmesartan medoxomil
Description: Cohorts A and B: 2.5mg to 40mg olmesartan, as a suspension (depending on weight), once daily. Tablets were used to prepare a suspension.~Cohort C: 0.3mg/kg olmesartan ,as a suspension, once daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: placebo
Description: Cohorts A, B, C: placebo, once daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: olmesartan medoxomil
Description: Cohorts A and B: Open label olmesartan medoxomil suspension or tablets 10mg - 40 mg. Tablets were used to prepare the suspension or were given directly.~Cohort C: Open label olmesartan medoxomil suspension 0.3 mg/kg - 0.6 mg/kg
Study: NCT02539329

Intervention type: OTHER
Intervention: Neurological assessment and Blood sample
Description: Neurological assessment (physical examination, electroneuromyography , International Prognostic Score (ISS), Overall Disability Scale (ODS), Rankin score) and 2 blood collection tubes for antibody screening

Intervention type: OTHER
Intervention: Neurological assessment and Blood sample
Description: Neurological assessment (physical examination, electroneuromyography , International Prognostic Score (ISS), Overall Disability Scale (ODS), Rankin score) and 2 blood collection tubes for antibody screening
Study: NCT04121468

Intervention type: DRUG
Group type: OTHER
Intervention: Metformin
Description: Each tablet contains 500mg of metformin hydrochloride

Intervention type: DRUG
Group type: OTHER
Intervention: Metformin
Description: Each tablet contains 500mg of metformin hydrochloride

Intervention type: DRUG
Group type: OTHER
Intervention: Metformin
Description: Each tablet contains 500mg of metformin hydrochloride

Intervention type: OTHER
Group type: OTHER
Intervention: Placebo
Description: Each tablet contains no active drug ingredient

Intervention type: OTHER
Group type: OTHER
Intervention: Placebo
Description: Each tablet contains no active drug ingredient

Intervention type: OTHER
Group type: OTHER
Intervention: Placebo
Description: Each tablet contains no active drug ingredient
Study: NCT03788239

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Staples versus sutures
Description: Prolene suture: non-absorbable, sterile surgical suture composed of an isotactic crystalline steroisomer of polypropylene, a synthetic linear polyolefin. After completion of the procedure, deep tissues will closed with subcuticular prolene suture. Compared to the absorbable sutures, prolene is known to cause less infection since it is a monofilament material.~Staples: specialized staples used in surgery in place of sutures to close skin wounds. After completion of the procedure, deep tissues were closed with absorbable braided suture, then the skin will be closed by staples.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Staples versus sutures
Description: Prolene suture: non-absorbable, sterile surgical suture composed of an isotactic crystalline steroisomer of polypropylene, a synthetic linear polyolefin. After completion of the procedure, deep tissues will closed with subcuticular prolene suture. Compared to the absorbable sutures, prolene is known to cause less infection since it is a monofilament material.~Staples: specialized staples used in surgery in place of sutures to close skin wounds. After completion of the procedure, deep tissues were closed with absorbable braided suture, then the skin will be closed by staples.
Study: NCT00470301

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: tipifarnib
Description: Given orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: paclitaxel
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: doxorubicin
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cyclophosphamide
Description: Given IV
Study: NCT02177461

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Enalapril

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Enalapril

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Clonidine

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Clonidine
Study: NCT01400607

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Neocartilage Implant/DeNovo® ET (Engineered Tissue Graft)
Description: The Neocartilage Implant is a cartilage repair technology cultured from juvenile human cartilage cells.

Intervention type: OTHER
Group type: OTHER
Intervention: Microfracture
Description: Marrow stimulation using the microfracture technique; performed arthroscopically
Study: NCT02947646

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: BabyGentleStick™ ON
Description: experimental intervention

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: BabyGentleStick™ ON
Description: experimental intervention

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: BabyGentleStick™ OFF
Description: active comparator

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: BabyGentleStick™ OFF
Description: active comparator
Study: NCT00952029

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: bevacizumab

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: bevacizumab

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FOLFIRI regimen

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: FOLFIRI regimen

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: fluorouracil

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: fluorouracil

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: irinotecan hydrochloride

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: irinotecan hydrochloride

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: leucovorin calcium

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: leucovorin calcium
Study: NCT02174991

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rho-Kinase Inhibitor (AR-12286)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rho-Kinase Inhibitor (AR-12286)
Study: NCT01373658

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Yinyi stent
Description: subjects with Yinyi stent implantation
Study: NCT03106064

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Promoting independence in self-care
Description: The intervention will consist of an twice daily walking training, plus privileging trips to the toilet by walking (with support devices or with support from people) and all daytime meals seated (not in bed). Attending of the particular and unexplored characteristics of the proposed intervention, namely the use of the toilet and meals, the proposed intervention extends throughout the 24 hours of the day, seven days a week.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Usual Care
Description: Usual hospital care
Study: NCT04569292

Intervention type: OTHER
Intervention: No intervention on patients
Description: No intervention on patients
Study: NCT01862523

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Capsaicin
Description: Thirty-three\* well-characterized IR patients will be recruited and screened for participation in this study with nasal capsaicin spray (0,1 mmol/l ) using the treatment regimen described by van Rijswijk et al. (1 x 5 applications in one day, with 1 hour between each application)

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: diluent
Description: diluent
Study: NCT00123318

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: epirubicin
Description: 50mg/m2 IV day 1

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cisplatin
Description: 60mg/m2 IV day 1

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 5-fluorouracil
Description: 5-FU 200mg/m2/d IV 21 day continuous infusion Cont. infusional 5-FU 225mg/m2/day, 7 days/wk throughout entire period RT via CADD pump through PICC line

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiotherapy
Description: 45Gy 25 Fractions, 5 days/week for 5 weeks
Study: NCT04270708

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine
Description: Patients with Autism will be treated with intranasal Dexmedetomidine as a sedative for EEG

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Triclofos 100 MG/ML
Description: Patients with Autism will be treated with oral Triclofos as a sedative for EEG
Study: NCT04200690

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Interdisciplinary management
Description: The intervention in this trial consists of the combined efforts of the interdisciplinary team in the combined clinic arm.~The interdisciplinary team consists of dermatologists, gastroenterologists, rheumatologists, nurses, psychologists, dieticians, social workers, physiotherapists, and secretaries. Treatment will be individualized based on clinical, biomarker, phenotypic, and psychosocial characteristics. The medical treatment will follow local, national and international guidelines.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Usual-care management
Description: Usual care will be carried out by HCPs that are not otherwise involved in the trial. In usual care the patients will not be offered an interdisciplinary patient-centered care as described, but only attend their usual disease-specific departments at the usual appointments.Treatment will be prescribed as felt appropriate according to local, national and international guidelines by the treating physicians with no set protocol and no restrictions.
Study: NCT04233203

Intervention type: DRUG
Intervention: Insulin Faster Aspart
Description: Currently receiving Faster Aspart during 3 or more months.

Intervention type: DEVICE
Intervention: Insulin pump
Description: Currently receiving CSII therapy during 6 or more months.
Study: NCT00075621

Intervention type: DRUG
Group type: OTHER
Intervention: filgrastim
Description: 16 mg/kg/day for 3 days prior to stem cell collection, through day before last collection

Intervention type: DRUG
Group type: OTHER
Intervention: melphalan
Description: 200 mg/kg over 2 days

Intervention type: PROCEDURE
Group type: OTHER
Intervention: autologous peripheral blood stem cell transplantation
Description: autologous peripheral blood stem cell transplantation